Neuroendocrine tumor

Perspective Therapeutics Divests Brachytherapy Business

Retrieved on: 
Tuesday, December 12, 2023
Brain, Tax, Lead, Intellectual property, Perspective, Sale, Seed, Software, Acquisition, Lung, Therapy, Neuroendocrine tumor, Isotope, Prostate, Brachytherapy, Patient, CATX, Radiation

SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy business, including its radioactive Cesium-131 seed assets and related business infrastructure, to GT Medical Technologies, Inc. (“GT Medical”).

Key Points: 
  • SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy business, including its radioactive Cesium-131 seed assets and related business infrastructure, to GT Medical Technologies, Inc. (“GT Medical”).
  • “At Perspective Therapeutics, we are relentlessly focused on realizing the therapeutic potential for the best possible isotopes that can be used to benefit patients with difficult-to-treat oncological indications," said Perspective Therapeutics CEO Thijs Spoor.
  • “The sale of our brachytherapy business marks a key strategic re-prioritization that allows us to focus on and dedicate resources towards accelerating the clinical development of our proprietary alpha-particle therapy portfolio.
  • “As a longstanding customer, we are impressed by the infrastructure that Perspective Therapeutics established for its Cesium-131 brachytherapy business,” said GT Medical Technologies CEO Matthew Likens.

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT

Retrieved on: 
Tuesday, October 18, 2022
Biotechnology, Radiology, Pharmaceutical, Health, LinkedIn, Mallinckrodt Institute of Radiology, Time, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Therapy, European Association of Nuclear Medicine, Review, Neoplasm, Neuroendocrine tumor, NYSE, Wilms' tumor, Seed, Twitter, Security (finance), Radiology, Multimedia, Viewpoint, Washington University in St. Louis, 8-K, Doctor of Philosophy, Association, Nuclear medicine, ISR, Toxicity, EDT, Clinical trial, European Association of Urology, Forward-looking statement, Peptide, Cancer, Medical imaging, IsoRay

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.

Key Points: 
  • Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds.
  • Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com .
  • Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.
  • These forward-looking statements (except as may be otherwise noted) speak only as of the date of this press release.

Incyte Names New Member to Its Board of Directors

Retrieved on: 
Tuesday, October 4, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Rubius, Solution, Time, Immunology, Novartis, Hematology, Transplant, Industry, Research, U.S. Securities and Exchange Commission, Neuroendocrine tumor, Growth, Therapy, Â, Security (finance), Patient, Board of directors, Annual report, Board, Marketing, Company, Management, Pharmaceutical industry, Incyte, Director

Incyte (Nasdaq:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors.

Key Points: 
  • Incyte (Nasdaq:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors.
  • On behalf of the Incyte Board of Directors, I am happy to welcome Susanne.
  • Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susannes contributions to our continued growth and future success, said Herv Hoppenot, Chief Executive Officer, Incyte.
  • I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need.

Ibex Announces Galen™ 3.0 Cancer Diagnostics Platform

Retrieved on: 
Sunday, September 4, 2022
Breast, Deep, Technology, Cancer, Research, Application, Deep learning, Squamous cell carcinoma, Artificial intelligence, Pathology, Solution, Gleason, Subjectivity, Physician, Product management, Marie Cassidy, LinkedIn, API, Diagnosis, Neuroendocrine tumor, Laboratory, Hospital, Version 3.0 (album), Lymphoma, TEL, Twitter, Algorithm, European Congress of Radiology, Prostate, Carcinoma in situ, Report, Review, AI, Medical imaging, Ibex

TEL AVIV, Israel, Sept. 4, 2022 /PRNewswire/ -- Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, today announced the launch and roll-out of Galen™ 3.0, a transformative solution offering new detection capabilities and a broad set of features to support pathologists in the diagnosis of multiple tissue types across various digital pathology workflows. Galen 3.0 is CE-Marked, approved in additional countries and now generally available to Ibex customers.  

Key Points: 
  • Galen 3.0 is CE-Marked, approved in additional countries and now generally available to Ibex customers.
  • Galen 3.0 incorporates the very latest evolution of Ibex's AI algorithms for detecting cancer and other clinically relevant features in prostate, breast, and gastric biopsies.
  • Galen also calculates a Gleason score, tumor size and percentage for each cancer slide, potentially enabling pathologists to save review time and reduce subjectivity.
  • Ibex is transforming cancer diagnostics with world-leading, clinical grade AI-powered solutions, empowering physicians to provide accurate, timely and personalized cancer diagnosis for every patient.

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

Retrieved on: 
Tuesday, April 19, 2022
NET, Pancreas, Nausea, Thyroid disease, Adult, Pharmacotherapy, Somatostatin, Rash, Neuroendocrine tumor, Radiopharmaceutical, B cell, GLOBE, Anaphylaxis, Patient, Itch, Neoplasm, Inflammation, Tissue, Lung, NETS, SSTR2, Heart, Copper, Radiation, Diagnosis, History, Wilms' tumor, Nuclear medicine, Angioedema, Marketing, Safety, Physician, Disease, Vomiting, Flushing, Risk, Liver, Gastrointestinal tract, Prostate, Cancer, PET, Pharmaceutical industry, Medical imaging, Birth control, Copper (64Cu) oxodotreotide

ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market.

Key Points: 
  • ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market.
  • We are incredibly pleased with the overwhelming response to Detectnet that has warranted an increase in production.
  • At Curium, we are focused on redefining the experience of cancer through our trusted legacy in nuclear medicine.
  • We are very pleased with this increase in commercial capacity and are excited Detectnet will be even more accessible.

Seneca Therapeutics, Inc. to Present at the World Vaccine Congress in Washington, DC April 18-21, 2022

Retrieved on: 
Monday, April 18, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Carcinoma, STI, Research, Doctor of Philosophy, SVV, Seneca, Patient, Neoplasm, Genome, Neuroendocrine tumor, Forward-looking statement, Senecavirus, Safety, Therapy, Congress, Pharmaceutical industry

Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers will be presenting on Wednesday, April 20 at 12:10pm at the World Vaccine Congress in Washington, DC.

Key Points: 
  • Seneca Therapeutics, Inc. (STI), a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers will be presenting on Wednesday, April 20 at 12:10pm at the World Vaccine Congress in Washington, DC.
  • Seneca Therapeutics Senior Immunology Consultant, Michael Lacy, PhD will present a summary of prior research and three clinical trials done utilizing Seneca Valley Virus (SVV-001) delivered intravenously as a monotherapy.
  • Dr. Lacy will also discuss Senecas upcoming Phase I/II clinical trial in both Neuroendocrine tumor and carcinoma patients.
  • Finally, data will also be presented demonstrating the utility of SVV to express therapeutic transgenes (armed derivatives) and/or cancer antigens.

Radiomedix and Orano Med Announce the Initiation of the Phase II Multi-Center Clinical Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers

Retrieved on: 
Monday, January 3, 2022
Safety, PRRT, CGMP, Diagnosis, Neoplasm, NETS, Gastrointestinal tract, Cancer, FDA, Half-life, Lung, Prostate, GLOBE, PET, GMP, B cell, Laboratory, MD, Heart, NET, Somatostatin, Pancreas, Patient, Tissue, Neuroendocrine tumor, Radiopharmaceutical, TAT, Targeted alpha-particle therapy, Pharmaceutical industry, Medical imaging, Phase

This trial will evaluate the safety and effectiveness of 212Pb-DOTAMTATE (AlphaMedix) in Peptide Receptor Radionuclide Therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET).

Key Points: 
  • This trial will evaluate the safety and effectiveness of 212Pb-DOTAMTATE (AlphaMedix) in Peptide Receptor Radionuclide Therapy (PRRT) of naive patients with somatostatin receptor-expressing neuroendocrine tumors (NET).
  • Targeted alpha therapy (TAT) with 212Pb-DOTAMTATE has been shown to be well-tolerated and preliminaryefficacy results are highly promising.
  • This milestone highlights the strength of collaboration between RadioMedix and Orano Med teams dedicated to makingtargeted alpha-emitter therapy with AlphaMedix available to NET patients, said Dr. Izabela Tworowska, Chief Scientific Officer of RadioMedix.
  • RadioMedix, Inc. is a clinical-stage biotechnology company, and sponsor of the AlphaMedix trial, based in Houston and Humble, Texas.

Global Neuroendocrine Tumors Drug Forecast and Market Analysis to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 29, 2021
Health, Pharmaceutical, Lutetium (177Lu) oxodotreotide, ALL, Patent, KOL, Neoplasm, Patient, Growth, Standard of care, Neuroendocrine tumor, Oil

Among the late-stage pipeline products and marketed agents, there is tempered key opinion leader (KOL) excitement as a fundamental change in the field is not expected until the end of the forecast period.

Key Points: 
  • Among the late-stage pipeline products and marketed agents, there is tempered key opinion leader (KOL) excitement as a fundamental change in the field is not expected until the end of the forecast period.
  • The most important unmet needs in the ALL market include: Predictive biomarkers to guide personalized therapy, safer targeted therapies for patients with low-grade tumors, and more efficacious therapies for high-grade tumors.
  • Five late-stage pipeline agents are expected to enter the Neuroendocrine Tumor market from 2021 onwards.
  • What are the current unmet needs in Neuroendocrine Tumors, which pipeline agents are positioned to counter these unmet needs?

JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions

Retrieved on: 
Thursday, August 26, 2021
NET, Master of Science, Strathcona County, Research, Neuroendocrine tumor, Harborside, Health, Review, Risk, Journal of the National Comprehensive Cancer Network, Comorbidity, Medicine, University, Metabolism, Survival, Policy, Death, Wilms' tumor, Clarivate, Patient, National Comprehensive Cancer Network, MD, Metastasis, Twitter, Report, Diagnosis, Female, Division, Cancer, Public policy, Mortality, Education, Stomach, Oncology, University of Toronto, NETS, ICES, Decision-making, Population, Bioethics, Caregiver, NCCN, Neoplasm, Fred, Pharmaceutical industry, Medical imaging

"Our results show that some patients with non-metastatic NETs are more likely to die of other causes than NET.

Key Points: 
  • "Our results show that some patients with non-metastatic NETs are more likely to die of other causes than NET.
  • This is crucial to inform patients and make decisions regarding treatment.
  • It is important to make sure that treatment does not present a higher risk than the NET itself.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .

JNCCN Study Reveals Neuroendocrine Tumor Mortality Patterns to Inform Treatment Decisions

Retrieved on: 
Thursday, August 26, 2021
NET, Master of Science, Strathcona County, Research, Neuroendocrine tumor, Harborside, Health, Review, Risk, Journal of the National Comprehensive Cancer Network, Comorbidity, Medicine, University, Metabolism, Survival, Policy, Death, Wilms' tumor, Clarivate, Patient, National Comprehensive Cancer Network, MD, Metastasis, Twitter, Report, Diagnosis, Female, Division, Cancer, Public policy, Mortality, Education, Stomach, Oncology, University of Toronto, NETS, ICES, Decision-making, Population, Bioethics, Caregiver, NCCN, Neoplasm, Fred, Pharmaceutical industry, Medical imaging

PLYMOUTH MEETING, Pa., Aug. 26, 2021 /PRNewswire/ -- Among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varies by primary tumor site, according to a new study published in the August 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network. It is the first population-based cohort study to describe factors associated with cancer-specific death after a NET diagnosis.

Key Points: 
  • Populationbased cohort study from Canada is first to describe patterns of mortality, both cancer-related and otherwise, for people with different types of NETs.
  • This is crucial to inform patients and make decisions regarding treatment.
  • It is important to make sure that treatment does not present a higher risk than the NET itself.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .